Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health (NASDAQ:JAGX) has reported statistically significant improvement in breast cancer patients in its Phase 3 OnTarget trial for crofelemer, a cancer supportive care drug. The trial evaluated crofelemer for prophylaxis of cancer therapy-related diarrhea. Breast cancer patients accounted for nearly 180 of the 287 participants in this prophylactic clinical trial.
While the initial top line results did not meet the primary estimand for all tumor types, the subgroup analysis in adult breast cancer patients showed clinically meaningful improvement. This suggests crofelemer's potential to help breast cancer patients better adhere to their cancer therapies. The results have been submitted to a relevant oncology conference, and a full study report is expected to be submitted to a peer-reviewed journal.
Additionally, crofelemer has shown benefit in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), with results to be presented at the upcoming American College of Gastroenterology Annual Scientific Meeting.
Jaguar Health, Inc. (NASDAQ:JAGX) announced that Stacey Tinianov, MPH, a member of Jaguar's Scientific Advisory Board, will present a poster at the American Society of Clinical Oncology (ASCO) Quality Care Symposium on September 27, 2024. The presentation, titled 'Measuring what really matters: Advocacy-led co-creation and accrual of a pan-cancer QoL survey,' will discuss the methodologies used in designing the 'More Than a Diagnosis' quality of life survey for cancer patients and survivors.
The survey, sponsored by Jaguar's family company Napo Pharmaceuticals, aims to address the limitations of commonly used tools in assessing cancer patients' quality of life concerns. Tinianov emphasized that while cancer treatments have advanced, significant side effects can still impact patients' quality of life. The presentation will highlight the importance of understanding patients' priorities to improve supportive care and effectively address quality of life impacts.
Jaguar Health, Inc. (NASDAQ:JAGX) has announced its participation in the Lytham Partners Fall 2024 Investor Conference, scheduled for October 1, 2024. The virtual event will feature a webcasted presentation by Lisa Conte, the company's founder, president, and CEO, at 1:15pm Eastern. Investors can access the webcast through a provided link, with a replay available after the event.
In addition to the presentation, Jaguar Health's management team will be available for one-on-one virtual meetings with investors throughout the conference. Interested parties can arrange meetings by contacting Lytham Partners or registering for the event through the provided link.
Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Pharmaceuticals, will exhibit Gelclair, an FDA-approved oral mucositis prescription product, at the American Society for Radiation Oncology (ASTRO) Annual Meeting from September 29 to October 2, 2024, in Washington, DC. Jaguar plans to launch Gelclair commercially in the U.S. in October 2024.
Gelclair is a protective gel that manages pain by adhering to the mouth's mucosal surface, providing relief for oral lesions, including those caused by oral mucositis/stomatitis. Unlike other products, it doesn't numb or sting the mouth. Oral mucositis, also known as "chemo mouth," affects up to 40% of chemotherapy patients and 90% of head and neck cancer patients treated with chemotherapy and radiotherapy. It can lead to hospitalization, treatment delays, and increased management costs.
The economic impact is significant, with a study showing that severe mucositis/pharyngitis in head and neck cancer patients can result in incremental costs exceeding $17,244 per patient. Jaguar aims to raise awareness among oncologists about Gelclair and its expanding focus on cancer supportive care at the ASTRO Annual Meeting.
Jaguar Health (NASDAQ:JAGX) has announced that its founder, president, and CEO, Lisa Conte, will present at the MedInvest Biotech & Pharma Investor Conference on September 19, 2024, in New York City. The presentation is scheduled for 9:55 AM to 10:10 AM Eastern time. Conte will also participate in one-on-one meetings during the event, which runs from September 18-19.
This conference provides Jaguar Health with an opportunity to showcase its developments and connect with potential investors in the biotech and pharmaceutical sectors. Interested parties can register for the presentation through a provided link, allowing them to gain insights into Jaguar Health's current projects and future prospects.
Jaguar Health (NASDAQ:JAGX) has appointed Susan Krizancic as National Sales Director for its family company Napo Pharmaceuticals. Krizancic, a biopharmaceutical industry veteran with 30 years of experience, will lead sales for Jaguar's commercialized oncology and HIV products. This includes the planned October 2024 launch of Gelclair, an FDA-approved oral mucositis prescription product for cancer supportive care.
Krizancic's appointment is expected to bolster Jaguar's commercial strategy, particularly in cancer and GI supportive care. The company will also continue to focus on sales of crofelemer (Mytesi), its FDA-approved drug for noninfectious diarrhea in adult HIV/AIDS patients on antiretroviral therapy. Jaguar's CEO, Lisa Conte, expressed confidence in Krizancic's ability to drive sales and execute the company's in-licensing growth strategy.
Jaguar Health (NASDAQ:JAGX) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. The company's founder, president, and CEO, Lisa Conte, will deliver a virtual presentation and meet with investors during the event.
The conference will be held both virtually and in-person at the Lotte New York Palace. Jaguar Health's on-demand virtual presentation will be available starting at 7:00 AM Eastern on Monday, September 9, 2024. Interested parties can access the presentation through a provided webcast link and register for the conference online.
This event presents an opportunity for Jaguar Health to showcase its developments and engage with potential investors, potentially impacting its stock performance and market visibility.
Jaguar Health (NASDAQ:JAGX) is celebrating National Service Dog Month, highlighting its commitment to supportive cancer care for both humans and dogs. The company's FDA conditionally approved drug, Canalevia-CA1, is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs.
Canalevia-CA1, a canine-specific formulation of crofelemer, is available by prescription from veterinarians and on Chewy. Jaguar's ongoing 'Make Cancer Less Shitty' campaign emphasizes the challenges of cancer treatments, especially for metastatic patients. The campaign features patient ambassadors sharing their experiences on the website makecancerlessshitty.com and on X under the handle cancersuckless.
Jaguar's CEO, Lisa Conte, stressed the alignment between service dogs' role in improving quality of life and Jaguar's mission to provide supportive care for complex diseases like cancer in both people and dogs.
Jaguar Health (NASDAQ:JAGX) has announced key near-term milestones in a new Innovators with Jane King interview with CEO Lisa Conte. The company is focusing on two main activities:
1. Planned October 2024 commercial launch of FDA-approved oral mucositis prescription product Gelclair® in the U.S.
2. Progressing rare disease development with multiple investigator-initiated proof-of-concept studies for crofelemer in microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). Results are expected by the end of 2024 and throughout 2025.
Jaguar also plans to enroll first patients for two global phase 2 studies for MVID and SBS-IF in Q4 2024. The company is continuing analysis of its pivotal phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea, with a focus on breast and lung cancer patients.
Jaguar Health (NASDAQ:JAGX) announced that Jordan's Industrial Property Protection Directorate has issued a new patent to Napo Pharmaceuticals for methods of treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal using crofelemer. This patent strengthens Jaguar's intellectual property protection for its core rare disease target indication of SBS.
Jaguar is supporting independent investigator-initiated proof-of-concept studies for crofelemer in SBS and microvillus inclusion disease (MVID) across the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025. These studies could potentially support early patient access to crofelemer in specific EU countries.
Napo currently holds approximately 173 patents and 60 patents pending. Crofelemer is the only oral plant-based prescription medicine approved under the FDA's Botanical Guidance, providing additional exclusivity advantages.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
